A quantitative method for the selective 5-HT2A agonist 25CN-NBOH in rat plasma and brain
- PMID:33784574
- DOI: 10.1016/j.jpba.2021.114016
A quantitative method for the selective 5-HT2A agonist 25CN-NBOH in rat plasma and brain
Abstract
In recent years, agonists of the 5-HT2A receptor have gained increasing attention for their potential therapeutic use to treat psychological disorders such as anxiety and depression. Here, we report the development and validation of an LC-MSMS based analytical method for the quantification of the novel selective 5-HT2A agonist 25CN-NBOH in rat plasma and brain. As simple and efficient sample clean-up we applied the Phree Phospholipid Removal approach from Phenomenex, which is particularly novel for brain samples. In order to investigate the metabolic stability of 25CN-NBOH in vitro biotransformation studies with recombinant enzymes and human liver microsomes were conducted. Several biotransformation products and pathways could be identified. Based on the in vitro study one of the putative metabolites (2C-CN) was included in the analytical method development. To test the methods applicability 25CN-NBOH was quantified in plasma and brain samples from a pharmacokinetic in vivo study with Wildtype Long Evans rats. Both the in vitro metabolism data as well as the in vivo PK data suggest that 25CN-NBOH is susceptible to metabolism, but is degraded slower and is more stable compared to other NBOMe's investigated to date. The developed analytical method might serve as basis to include further 25CN-NBOH metabolites. It is expected to facilitate further preclinical and clinical investigations of 25CN-NBOH in biological matrices.
Keywords: 25CN-NBOH; 5-HT(2A) agonist; LC-MSMS; Metabolism; Pharmacokinetics; Phospholipid removal.
Copyright © 2021 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest None.
Similar articles
- The selective 5-HT2A receptor agonist 25CN-NBOH: Structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [3H]25CN-NBOH.Jensen AA, Halberstadt AL, Märcher-Rørsted E, Odland AU, Chatha M, Speth N, Liebscher G, Hansen M, Bräuner-Osborne H, Palner M, Andreasen JT, Kristensen JL.Jensen AA, et al.Biochem Pharmacol. 2020 Jul;177:113979. doi: 10.1016/j.bcp.2020.113979. Epub 2020 Apr 13.Biochem Pharmacol. 2020.PMID:32298690
- Detailed Characterization of the In Vitro Pharmacological and Pharmacokinetic Properties ofN-(2-Hydroxybenzyl)-2,5-Dimethoxy-4-Cyanophenylethylamine (25CN-NBOH), a Highly Selective and Brain-Penetrant 5-HT2A Receptor Agonist.Jensen AA, McCorvy JD, Leth-Petersen S, Bundgaard C, Liebscher G, Kenakin TP, Bräuner-Osborne H, Kehler J, Kristensen JL.Jensen AA, et al.J Pharmacol Exp Ther. 2017 Jun;361(3):441-453. doi: 10.1124/jpet.117.239905. Epub 2017 Mar 30.J Pharmacol Exp Ther. 2017.PMID:28360333
- 25CN-NBOH: A Selective Agonist for in vitro and in vivo Investigations of the Serotonin 2A Receptor.Märcher Rørsted E, Jensen AA, Kristensen JL.Märcher Rørsted E, et al.ChemMedChem. 2021 Nov 5;16(21):3263-3270. doi: 10.1002/cmdc.202100395. Epub 2021 Aug 21.ChemMedChem. 2021.PMID:34288515Review.
- Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen.Halberstadt AL, van der Zee JVF, Chatha M, Geyer MA, Powell SB.Halberstadt AL, et al.Psychopharmacology (Berl). 2019 Feb;236(2):821-830. doi: 10.1007/s00213-018-5118-y. Epub 2018 Nov 17.Psychopharmacology (Berl). 2019.PMID:30448990Free PMC article.
- DARK Classics in Chemical Neuroscience: NBOMes.Poulie CBM, Jensen AA, Halberstadt AL, Kristensen JL.Poulie CBM, et al.ACS Chem Neurosci. 2020 Dec 2;11(23):3860-3869. doi: 10.1021/acschemneuro.9b00528. Epub 2019 Nov 12.ACS Chem Neurosci. 2020.PMID:31657895Free PMC article.Review.
Cited by
- Development and validation of LC-MS/MS method for determining the metabolic stability, pharmacokinetics, and dose proportionality of a novel anti-inflammatory cofilin inhibitor.Alsegiani AS, Shah ZA.Alsegiani AS, et al.J Pharm Biomed Anal. 2023 Mar 20;226:115258. doi: 10.1016/j.jpba.2023.115258. Epub 2023 Jan 24.J Pharm Biomed Anal. 2023.PMID:36709658Free PMC article.
- Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.Cumming P, Scheidegger M, Dornbierer D, Palner M, Quednow BB, Martin-Soelch C.Cumming P, et al.Molecules. 2021 Apr 22;26(9):2451. doi: 10.3390/molecules26092451.Molecules. 2021.PMID:33922330Free PMC article.Review.
- Analysis of 2,5-dimethoxy-amphetamines and 2,5-dimethoxy-phenethylamines aiming their determination in biological matrices: a review.Nieddu M, Baralla E, Sodano F, Boatto G.Nieddu M, et al.Forensic Toxicol. 2023 Jan;41(1):1-24. doi: 10.1007/s11419-022-00638-6. Epub 2022 Sep 14.Forensic Toxicol. 2023.PMID:36652064Free PMC article.Review.
- In Vitro andIn Vivo Evaluation of Pellotine: A HypnoticLophophora Alkaloid.Poulie CBM, Chan CB, Parka A, Lettorp M, Vos J, Raaschou A, Pottie E, Bundgaard MS, Sørensen LME, Cecchi CR, Märcher-Rørsted E, Bach A, Herth MM, Decker A, Jensen AA, Elfving B, Kretschmann AC, Stove CP, Kohlmeier KA, Cornett C, Janfelt C, Kornum BR, Kristensen JL.Poulie CBM, et al.ACS Pharmacol Transl Sci. 2023 Sep 18;6(10):1492-1507. doi: 10.1021/acsptsci.3c00142. eCollection 2023 Oct 13.ACS Pharmacol Transl Sci. 2023.PMID:37854625Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials